Voyageur Pharmaceuticals ( (TSE:VM) ) has shared an announcement.
Voyageur Pharmaceuticals Ltd. has granted 955,045 Deferred Share Units (DSUs) to its directors as part of its equity incentive compensation plan. This move aligns with the company’s strategy to compensate its directors and strengthen its governance structure. The DSUs, which are subject to TSX Venture Exchange approval, reflect Voyageur’s commitment to aligning the interests of its board with its strategic goals. This announcement underscores Voyageur’s ongoing efforts to solidify its market position and enhance its operational efficiency as it transitions into a high-margin domestic manufacturer of radiology drugs.
More about Voyageur Pharmaceuticals
Voyageur Pharmaceuticals Ltd. is a Canadian public company focused on developing barium and iodine Active Pharmaceutical Ingredients (API) and aims to offer high-performance, cost-effective imaging contrast agents. The company plans to vertically integrate the barium and iodine contrast markets and has developed five barium contrast products with Health Canada licenses. Voyageur owns the Frances Creek barium sulphate project and seeks to become the first vertically integrated company in the radiology contrast media drug market.
YTD Price Performance: 67.95%
Average Trading Volume: 36,347
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $19.21M
See more data about VM stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com